Board of Directors
Johannes Fruehauf (Cambridge Biolabs), Peter Parker (BioInnovation LLC), and Tim Rowe (Cambridge Innovation Center) have created LabCentral based on their own experiences as entrepreuneurs and that of countless others who have spent precious time and resources searching for and equipping appropriate startup lab space. Clearly, there is a glaring need for such a facility centered in and around Cambridge and Boston designed specifically for the life-sciences community.
Johannes Fruehauf, MD, PhD
CEO, Cambridge Biolabs and ViThera Pharma; Cofounder, Cequent Pharmaceuticals
Johannes Fruehauf (MD PhD) has a background as a physician working in diverse health systems. In his 15+ years as a serial biotech entrepreneur, Dr. Fruehauf has dedicated much of his professional endeavors to the mission of re-defining life science entrepreneurship and building start-up ecosystems.
He is the Founder and President of LabCentral, the preeminent private/public partnership model for life science incubator space, while also serving as CEO for BioLabs, the largest provider of laboratory co-working space for startups nationwide. LabCentral and Biolabs currently are home for over 300 startups in 8 cities and companies started within this network now routinely account for over 20% of all Seed and Series A venture capital invested in life sciences in the US.
Johannes is founder and General Partner of Mission BioCapital (MBC). In his role at MBC, he sources, diligences, and leads new life-science investment transactions and represents the fund on the board of a number of MBC portfolio companies.
Dr. Fruehauf studied medicine in Germany and France, while also conducting field work in Africa (Zimbabwe and Guinea). He graduated from University of Frankfurt and received his doctorate from the University of Heidelberg. Johannes is the author of over 30 peer reviewed publications and is named inventor on 9 patents.
Managing General Partner, BioInnovation Capital; General Partner, Ampersand Ventures; Founding CEO, Boston Heart Dx; CEO, Cequent Pharma
Peter Parker is a founder and director of LabCentral. He chairs the selection committee and overseas board activities. He also conducts seed and early-stage life-sciences investing activities through BioInnovation Capital based in Cambridge, Mass. For the past several years, Peter has played a major role in the greater Boston/Cambridge healthcare start-up community. At MassChallenge, he was the healthcare/life sciences ‘Champion’ for five years. He is also a co-founder of BioLabs and several other local firms including Boston Heart Diagnostics, Deltix, and 5G Bio. LabCentral was born out of Peter’s and Johannes’ difficult search for lab space when they formed Cequent Pharmaceuticals together in 2006. For nearly 20 years, Peter was a general partner at Ampersand Capital Partners, Wellesley, Mass. He has been a board member and investor in more than 25 life sciences companies.
CEO, MassChallenge; Bain & Company
John Harthorne is the Founder and Former CEO of MassChallenge, the most startup-friendly accelerator on the planet. To date, ~2,500 MassChallenge alumni have raised over $6 billion of funding, have generated over $3 billion of revenue, and have created over 157,000 jobs.
The World Economic Forum elected John as one of the 2013 Young Global Leaders, and Ernst & Young selected John as Social Entrepreneur of the Year in New England for 2013. The Boston Business Journal has also identified John as one of “Boston’s 50 Most Influential Business Leaders.”
John stepped down as CEO of MassChallenge in 2019 to launch Two Lanterns Venture Partners, a seed fund focused on capital-efficient startups poised to create massive impact.
Director, Chairman of the Board
CEO, Forma Therapeutics; Novartis Venture Fund; Novartis Strategic Alliances
Steve Tregay is the founder, president and CEO of FORMA Therapeutics, a company building a robust pipeline of transformative cancer therapeutics directed in areas such as tumor metabolism, epigenetics and protein-protein interactions. Prior to joining FORMA, Steven Tregay was a managing director for the $200 million Novartis Option Fund. He led the fund’s investments in and served on the board of directors of FORMA Therapeutics, Adenosine Therapeutics (acquired by Clinical Data: FRX) and Cequent Pharmaceuticals (acquired by Marina Biotech: MRNA). Prior to joining the venture group, he was the executive director and head of strategic alliances – Oncology, Ophthalmology and Technologies at the Novartis Institutes for BioMedical Research. He managed a team responsible for identification, negotiation and management of collaborations for the oncology and ophthalmology disease areas and all the technology areas. Prior to Novartis, he had roles in business development at Array BioPharma and research. He received his doctoral and master’s degrees in organic chemistry from Harvard University and a bachelor’s from Davidson College.
Susan Windham-Bannister, PhD, D.Sc
CEO, Biomedical Growth Strategies
Dr. Windham-Bannister received her B.A. from Wellesley College, a Doctorate in Health Policy and Management from the Florence Heller School at Brandeis University, and a Doctor of Science from Worcester Polytechnic Institute (honoris causa). She was a Post-Doctoral Fellow at Harvard University's John F. Kennedy School and a Fellow in the Center for Science and Policy (CSAP) at Cambridge University, Cambridge, England. She completed her doctoral work at the Heller School under a fellowship from the Ford Foundation.
Dr. Windham-Bannister currently serves as president and CEO of Biomedical Growth Strategies, where she provides strategic advisory services to life-sciences initiatives in the U.S. and abroad.
Previously, Dr. Windham-Bannister served as the president and CEO of the Massachusetts Life Sciences Center (MLSC), an economic development and investment agency dedicated to supporting the growth and development of the life-sciences in Massachusetts. As CEO, she managed a $1B fund designated to invest in biotechnology, pharmaceuticals, medical devices, medical diagnostics and bioinformatics/analytics. She is the first African American in the U.S. to lead a life-sciences focused innovation fund of this scale and was responsible for the MLSC's investment strategy, brand management, organizational development, and ROI.
Jo Viney, PhD
President and CSO, Pandion Therapeutics, Inc.
Dr. Viney received her BSc in Biophysics at the University of East London and her PhD in Gut Immunology at the University of London (St Bartholomew’s Hospital Medical School). She went on to fill a Postdoctoral Research Fellowship at Imperial Cancer Research Fund (now Cancer Research UK), followed by a second Postdoctoral position at Genentech.
Dr. Viney currently serves as the founder, president, and chief scientific officer at Pandion Therapeutics, a clinical-stage biotechnology company working on developing a platform of modular biologics for treating autoimmune and inflammatory diseases. A wholly-owned subsidiary, Pandion was acquired earlier this year by Merck to accelerate its mission to transform the way patients living with autoimmune-related conditions are treated.
Prior to founding Pandion, Dr. Viney most recently served as Biogen’s Senior Vice President of Drug Discovery. Earlier in her career she was Amgen’s Executive Director for Inflammation Research and was the Director of Autoimmunity and Inflammation Research at Immunex prior to its acquisition by Amgen. In addition, she sits on the Board of Directors for Harpoon Therapeutics and Finch Therapeutics Group, as well as the Scientific Advisory Board at HotSpot Therapeutics. An advocate for diversity in the STEM field, Dr. Viney was also on the board and president of the non-profit, WEST (Women in the Enterprise of Science and Technology), which aims to help women reach their full potential early in their career.